Brexit Update: UK Medtech Industry Viewpoint, And One Notified Body's Strategy
Executive Summary
The case for and against Brexit is only becoming more complex as the months advance toward Brexit Day (March 29, 2019) and the December 2020 end of the UK transition/implementation period. Offering what support it can, UK medical device industry association ABHI held a Brexit information seminar in April. At the gathering, UK notified body BSI revealed the thinking behind its current plans.
You may also be interested in...
Brexit Points Of Order: Hard Brexit Plans Nearer As UK Remains Vague On Device-Sector Impact
The latest round of EU Brexit negotiations were bruising encounters for the UK, whose perceived selective approach to EU membership was rebuffed again. The talks coincided with the restatement of the government's position on device- and pharma-related Brexit issues. UK medtechs may well be looking at the June EU Council meeting as the point of no return.
UK Medtechs Get A Touch More Certainty With Brexit Transition Agreement
With the UK scheduled to leave the EU one year, the UK medtech and lifesciences industries were becoming increasingly concerned about the government's lack ofplanning and the risk of being left high and dry in the post-Brexit environment. But the UK has bought more time now that the EU agreed to a withdrawal transition phase until the end of 2020. There are potentially meaningful positives in the agreement for medtechs on either side of the English Channel.
UK Medtech To Leverage Accelerated Access Opportunity, Regardless Of The 'B' Word
The UK devices and diagnostics industries were quick to react to the long-overdue government response to the fall 2016 Accelerated Access Review, a proposal to fast-track innovation into the NHS to the benefit of UK science, patients and the economy. Coinciding with Brexit, it is a fine-sounding plan, but will there be practical follow-through for medtech too?